Valeritas (NSDQ:VLRX) touted data today from an analysis showing that insulin-dependent people with Type 2 diabetes benefited from using the company’s wearable V-Go insulin delivery device.
The study featured people who previously treated their diabetes using multiple daily injections of insulin. After switching to the V-Go device under the care of advanced practitioners, participants were monitored and evaluated at the three- and seventh-month mark.
After three months, researchers observed a mean change in A1c of -1.1% from the mean baseline of 9.1% and a mean total daily insulin dose of 58 units per day compared to a mean baseline of 87 units per day. After seven months, the mean change in A1c was -1.1% and the mean total daily insulin dose was 61 units per day, according to Valeritas.
“For many patients with Type 2 diabetes, being able to adhere to an insulin regimen consisting of multiple daily injections is a real challenge as it can be burdensome to daily living and complex,” Amanda Patricia Wakim, a nurse practitioner in Wheeling, West Virginia, said in prepared remarks.
“In my practice, V-Go has been well received by patients as it removes the need for multiple injections, is simple to use, and has enabled many of my patients to lower their glucose, use less insulin, and not gain the weight normally seen with intensified insulin therapy,” she added.
“Insulin only works if patients actually take it. For many, that includes taking it around each meal and away from their home,” president & CEO John Timberlake said. “This data from patients using V-Go prescribed by Advanced Practitioners is consistent with previously published data showing how patients can lower their blood glucose and do so using less insulin.”
